0.911
0.04 (4.00%)
| Previous Close | 0.876 |
| Open | 0.860 |
| Volume | 119,634 |
| Avg. Volume (3M) | 679,954 |
| Market Cap | 14,374,032 |
| Price / Sales | 19.05 |
| Price / Book | 10.70 |
| 52 Weeks Range | |
| Earnings Date | 15 May 2025 - 19 May 2025 |
| Operating Margin (TTM) | -19,313.33% |
| Diluted EPS (TTM) | -0.420 |
| Quarterly Revenue Growth (YOY) | -9.20% |
| Total Debt/Equity (MRQ) | 441.35% |
| Current Ratio (MRQ) | 0.330 |
| Operating Cash Flow (TTM) | -1.81 M |
| Levered Free Cash Flow (TTM) | -2.07 M |
| Return on Assets (TTM) | -38.38% |
| Return on Equity (TTM) | -531.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ABVC Biopharma, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | -0.13 |
|
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 18.05% |
| % Held by Institutions | 3.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Avantax Planning Partners, Inc. | 31 Dec 2024 | 143,968 |
| Spotlight Asset Group, Inc. | 30 Jun 2024 | 100 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |